SK Bioscience

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • Foreign exchange exposure hedged with currency forward contracts, contract amount KRW 21.99B, reducing FX risk impact on earnings
• • Derivative liabilities KRW 105.3M at fiscal year-end, down from KRW 1.66B prior year, largest single quantified derivative liability

Management Discussion & Analysis

• • Revenue KRW 651.4B (+143.5% YoY), operating loss KRW -123.5B (-10.8% deficit reduction), net loss KRW -56.2B (-12.1%)
• • IDT Biologika acquisition in Q4 2024 drove revenue growth and operational improvement

Business Overview

• • 2025 sales KRW 651.4B with 71.5% from CDMO, vaccine development 28.5%
• • June 2025 completion of pneumococcal vaccine production facility expansion at Andong L HOUSE

What are the latest SK Bioscience DART filings in 2026?

SK Bioscience (KRX code 302440) has filed an annual report on March 13, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did SK Bioscience file its most recent annual report?

SK Bioscience filed its most recent annual report on March 13, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is SK Bioscience's KRX stock code?

SK Bioscience's KRX stock code is 302440. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 302440 to look up all SK Bioscience disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does SK Bioscience file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for SK Bioscience.

Where can I find SK Bioscience financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from SK Bioscience annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.